To appraise the clinical and cost effectiveness of letermovir within its marketing authorisation for preventing cytomegalovirus reactivation or disease in people with sero-positive-CMV who have had an allogeneic haematopoietic stem cell transplant.
Status In progress
Process STA pre-2018
ID number 1153

Provisional Schedule

Expected publication 31 July 2019

Project Team

Project lead Kate Moore

Email enquiries

Evidence Review Group / Assessment Group Centre for Reviews and Dissemination and Centre for Health Economics – York


Companies sponsors Merck, Sharp & Dohme (letermovir)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Anthony Nolan
Professional groups Cancer Research UK
  Royal College of Pathologists
  Royal College of Physicians
  The British Society for Haematology


Comparator companies Actavis (CAU not returned, not participating)
  Accord Healthcare (CAU not returned, not participating)
  Aurobindo (CAU not returned, not participating)
  Clinigen (CAU not returned, not participating)
  GlaxoSmithKline (aciclovir, valaciclovir)
  Hospira (CAU not returned, not participating)
  Roche Products (CAU not returned, not participating)
  Rosemont (CAU not returned, not participating)
  Sun pharmaceutical (acyclovir, valacicilovir) (CAU not returned, not participating)
  Thame Labratories (CAU not returned, not participating)
  Thorton & Ross (CAU not returned, not participating)
  Wockhardt (CAU not returned, not participating)
General commentators All Wales Therapeutic and Toxicology Centre
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee


Key events during the development of the guidance:

Date Update
30 May 2019 - 13 June 2019 Final appraisal document
16 April 2019 Committee meeting: 2
31 July 2018 Following the release of the appraisal consultation document (ACD), we have suspended this appraisal. The company (Merck Sharp & Dohme) requested that NICE suspend this appraisal because it is considering its commercial arrangement for this product. Therefore, the basis for the decision making is likely to change and the appraisal committee meeting (previously scheduled for 8 August 2018) will be rescheduled.
04 July 2018 - 25 July 2018 Appraisal consultation: 1
12 June 2018 Committee meeting: 1
09 January 2018 Invitation to participate
14 July 2017 - 11 August 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
09 January 0008 In progress, Invitation to participate

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance